Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma

Zhihong Chen1,2, Xi Feng2, Cameron J Herting1

  • 1Department of Pediatrics and Aflac Cancer Center of Children's Health Care of Atlanta, Emory University School of Medicine, Atlanta, Georgia.

Cancer Research
|February 26, 2017
PubMed

Insights

Tumor-associated macrophages (TAM) in glioblastoma (GBM) include infiltrating monocytes and resident microglia. Targeting infiltrating monocytes, which are crucial for GBM growth, can improve survival.

Area of Science:

  • Neuro-oncology
  • Immunology
  • Cell biology

Background:

  • Tumor-associated macrophages (TAM) are key components of glioblastoma (GBM), comprising up to 50% of the tumor mass.
  • Understanding the dynamic interplay between infiltrating macrophages and resident microglia in GBM is crucial for developing effective therapies.

Purpose of the Study:

  • To investigate the temporal and spatial dynamics of TAM composition during gliomagenesis.
  • To differentiate the origins, localization, and functions of infiltrating macrophages versus resident microglia in GBM.

Main Methods:

  • Utilized genetically engineered and GL261-induced mouse models.
  • Employed CX3CR1GFP/WT;CCR2RFP/WT double knock-in mice for cell tracking.
  • Performed RNA-sequencing to analyze gene expression patterns.

Main Results:

  • Identified distinct monocyte (CX3CR1LoCCR2Hi) recruitment and subsequent transition to macrophages (CX3CR1HiCCR2Lo) and microglia-like cells (CX3CR1HiCCR2-) within GBM.
  • Demonstrated that infiltrating bone marrow-derived macrophages constitute ~85% of TAM, localizing perivascularly, while resident microglia (~15%) are found in peritumoral regions.
  • Showed that genetic reduction of CCL2, which limits monocyte infiltration, significantly prolonged survival in tumor-bearing mice.

Conclusions:

  • Glioblastoma TAM populations are heterogeneously composed of distinct infiltrating and resident myeloid cells with unique functions.
  • Infiltrating monocytes are critical for GBM progression, and targeting them offers a promising therapeutic strategy.